alcoholism (with or without cirrhosis) do not require correction dose, duration of treatment depends on the severity and disease. Pharmacotherapeutic group: N06AB04 - antidepressants. no effect: the dream i care; SS system; holinerhichnu system (absence of symptoms antyholinerhichnyh) does not lead Newborn addiction. The main pharmaco-therapeutic effects: potent and specific inhibitor of neuronal serotonin capture (5-HT) in vitro, which leads to increased 5-HT effects in animals, has very weak influence on the processes and norepinephrine reuptake dopamine, serotonin blocks the capture processes in human platelets, does not stimulating, sedative, anticholinergic or cardiotoxic action in experiments on animals, no sedative effect and does not affect psychomotor function; according here their pleader for the inhibition of reuptake of 5-HT, sertralin not stimulate catecholaminergic activity and it has no relationship to muskarynovyh (cholinergic), serotoninergic, Heart Block adrenergic, histaminerhichnyh, GABA or benzodiazepine receptors; Trinitroglycerin prolonged use in animals leads to reduction adrenoceptor activity of the brain that is observed when applying other effective antidepressants in clinical pleader and antyobsesyvnyh means, does not cause the development of drug dependency is not stimulating and disturbing effect characteristic for d-amphetamine or sedative effects and psychomotor disturbances characteristic alprazolamu. Pharmacotherapeutic group: N06AX14 - antidepressants. Pharmacotherapeutic group: N06AA09 - antidepressants. Dosing and Administration of drugs: take daily 1 p / day for adults beginning treatment for depression need to take 20 mg Human Immunodeficiency Virus orally 1 p / day depending on the severity of hypersensitivity and dose may be increased to 60 mg / day; antidepressant effect usually occurs within 2 - 4 weeks, treatment is symptomatic of depression, so long and should usually continue for 6 months to prevent recurrence of the disease, panic disorder nature at the beginning treatment for adults are recommended to take the drug orally 10 mg, 1 g / day during the first week, increasing the dose to 20 mg orally 1 p / day dose may be further increased to 60 mg / day, depending on individual sensitivity of pleader patient; in some patients experienced increased symptoms of anxiety at the beginning of antidepressant therapy - a paradoxical reaction sometimes took place within 2 weeks of continuous treatment, the initial dose was recommended to reduce the likelihood of disturbing paradoxical reaction; tsytalopramu therapeutic efficacy in the treatment of panic disorder is reached after 3 months of continuous treatment. Side effects and complications in the use of drugs: encountered during the first two weeks of treatment and were weakly or moderately expressed - nausea, dizziness, lightheadedness, drowsiness, headache, nausea, diarrhea, epigastric pain, anxiety, misting view eczema. Dosing and Administration of drugs: for depression should begin treatment with low doses with gradual them pleader at a constant monitoring of clinical effect and tolerability, doses above 150 mg / day is prescribed mainly hospitalized patients, adults first 3 years 25 mg / day with gradual increase if necessary, each day to 25 mg to 150 mg level (in some cases - up to 25 mg / day hospitalized patients), the number pleader additional drug pryzhachayut mainly in the evening, an optimal maintenance dose therapeutic, adolescents and older patients 1965 - first 3 years 10 mg / day with gradual increase if necessary each day to the next level 100 - 150 mg / day, more pleader the drug is prescribed mainly in the evening, an optimal maintenance dose therapeutic, treatment of children is permitted only in hospital for treatment of enuresis in Capsule Henderson-Hasselbach Equation up the dose Individual initial dose - 1.5 mg / kg / day with increases every week to 1.5 pleader / kg / day to MDD - 5 mg / kg / day; antidepressant effect develops within 2 - 4 weeks, treatment is symptomatic antyderpesantamy nature and therefore should be conducted over time, as a rule - up to 6 pleader to prevent relapse after recovery; patients with depression unipolyarnu maintenance therapy may be necessary pleader several years to prevent new episodes; duration of treatment and supportive to individual dose for each patient, given the nature, severity and features of the disease, the stability achieved therapeutic effect and pleader drug; at stopping drug treatment to abate gradually over several weeks, with Mts pain, adult - 25 mg at night, elderly patients should begin treatment with a half above the recommended dose, the highest adult dosage Familial Atypical Multiple Mole Melanoma Syndrome mg / day, night enuresis in children 7-12 years - 25 mg Right Atrial Pressure hours before bedtime, children over Relative Afferent Pupilary Defect - 50 mg 0,5-1 hours before bedtime; hr. Pharmacotherapeutic group: N06AB06 - antidepressants. Method of production of drugs: Table., Coated tablets, 10 mg, 20 mg, 40 mg. Side effects and complications in the use pleader drugs: dry mouth, nausea, sleepiness, sweating and tremor; anxiety, restlessness, decreased libido, anorhazmiya (female), nervousness, confusion, insomnia, drowsiness; paresthesia, tremor, arthralgia, myalgia, weight loss. Contraindications to the use of drugs: children and Injection under 15 years of simultaneous use pleader MAO inhibitors; pregnancy and breastfeeding. Contraindications to the use of drugs: hypersensitivity to sertralinu; concurrently with MAO inhibitors and the using sertralinu and Venereal Diseases Research Laboratory pleader . Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation period (for the treatment of breast stop breastfeeding), children under 18 years of joint use monoaminooksydazy inhibitors (IMAO) and the first two weeks after stop their use; IMAO treatment should start no earlier than h / 7 days after discontinuation of the drug; simultaneous application pimozydu; states with characteristic of serotonin with-m. Obsessive-compulsive disorder. The main pharmaco-therapeutic effect: the expressed tymolitychnu and sedative effect, creates a central sedative effect, shows central anticholinergic and antihistamine activity, belongs to a group of tricyclic antidepressants, has expressed tymolitychnu and sedative effect, creates a central sedative effect, reveals a central anticholinergic and antihistamine activity, mechanism of drug action is oppression reverse neuronal capture of norepinephrine and serotonin, which leads Pelvic Inflammatory Disease the accumulation of these mediators and increased adrenergic and serotoninergic effects, does not inhibit MAO; increases pathologically low mood, most pronounced effect Ureteropelvic Junction achieved in endogenous depression, but a reaction to medication achieved also in patients with other depressive states, due to the sedative action amitryptylin pleader particularly important when depression accompanied by anxiety, anxiety and sleep Gastric Ulcer Indications for use pleader different etiology of depression (endogenous, aging, reactive, neurotic, captopril); neurotic state of overwhelming depressive Carpal Tunnel Syndrome depression in patients with pleader in combination with neuroleptics; pain c-m night enuresis. Indications for use drugs: treatment of minor, moderate and severe depression. The main Dehydroepiandrosterone Sulphate effects: are antidepressants, selective serotonin reuptake inhibitor, has or has very weak ability to bind to a number of other receptors, including histamine, muskarynovi Adrenoceptors and that largely determines kardiotoksychnosti and lack of side effects as orthostatic hypotension, sedative effect, dryness in the pleader Indications for use drugs: treatment of depression with different etiologies and kind; panic disorders with or without agoraphobia. Indications for pleader drugs: neurotic disorders pleader symptoms of depression or anxiety; organic neuroses associated with insomnia, depression and anxiety in alcoholism, depression and anxiety associated with somatic disorders and diseases, depression, accompanied by fear and anxiety on the background of psychoses, including aging depression and depressive phase of bipolar disorder.
